NALED - search results

United States - English - NLM (National Library of Medicine)

medroxyprogesterone acetate injection, suspension, extended release

remedyrepack inc. - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate is indicated only for the prevention of pregnancy. the loss of bone mineral density (bmd) in women of all ages and the impact on peak bone mass in adolescents should be considered, along with the decrease in bmd that occurs during pregnancy and/or lactation, in the risk/benefit assessment for women who use medroxyprogesterone acetate long-term [see warnings and precautions (5.1)] . the use of medroxyprogesterone acetate is contraindicated in the following conditions: - known or suspected pregnancy or as a diagnostic test for pregnancy. - active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease [see warnings and precautions (5.2)] . - known or suspected malignancy of breast [see warnings and precautions (5.3)]. - known hypersensitivity to medroxyprogesterone acetate or any of its other ingredients [see warnings and precautions (5.5)] . - significant liver disease [see warnings and precautions (5.6)]. - undiagnosed vaginal bleeding [see warnings and precautions (5.9)] . medroxyprogesterone acetate should not be administered during pregnancy. [see contraindicationsand warnings and precautions (5.17).] detectable amounts of drug have been identified in the milk of mothers receiving medroxyprogesterone acetate. [see warnings and precautions (5.13).] medroxyprogesterone acetate is not indicated before menarche. use of medroxyprogesterone acetate is associated with significant loss of bmd. this loss of bmd is of particular concern during adolescence and early adulthood, a critical period of bone accretion. in adolescents, interpretation of bmd results should take into account patient age and skeletal maturity. it is unknown if use of medroxyprogesterone acetate by younger women will reduce peak bone mass and increase the risk of osteoporotic fractures in later life. other than concerns about loss of bmd, the safety and effectiveness are expected to be the same for postmenarchal adolescents and adult women. this product has not been studied in post-menopausal women and is not indicated in this population. the effect of renal impairment on medroxyprogesterone acetate pharmacokinetics has not been studied. the effect of hepatic impairment on medroxyprogesterone acetate pharmacokinetics has not been studied. medroxyprogesterone acetate should not be used by women with significant liver disease and should be discontinued if jaundice or disturbances of liver function occur. [see contraindications (4)and warnings and precautions (5.7).]

Israel - English - Ministry of Health

suprane

baxter healthcare distribution ltd., israel - desflurane - solution for inhalation - desflurane 100 % - desflurane - desflurane - sulorane is indicated as an inhalation agent for induction and/or maintenance of anesthesia in adults and maintenance of anesthesia in infants and children.

United Kingdom - English - myHealthbox

desflurane 100% (v/v) inhalation vapour, liquid

piramal healthcare uk limited - desflurane - inhalation vapour liquid - 100% (v/v) - nervous system; anesthetics; general; halogenated hydrocarbons - it is indicated as an inhalation agent for induction and maintenance of general anesthesia for inpatient and outpatient surgery in adults and for the maintenance of anaesthesia in infants and children.